Medicina
Departamento
Instituto de Investigación Sanitaria La Fe
Valencia, EspañaPublicaciones en colaboración con investigadores/as de Instituto de Investigación Sanitaria La Fe (60)
2024
-
Outcomes after intensive chemotherapy for secondary and myeloid-related changes acute myeloid leukemia patients aged 60 to 75 years old: a retrospective analysis from the PETHEMA registry
Haematologica, Vol. 109, Núm. 1, pp. 115-128
-
Real-life effectiveness of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients previously treated with sofosbuvir/velpatasvir or glecaprevir/pibrentasvir
Alimentary Pharmacology and Therapeutics
2023
-
A second update on mapping the human genetic architecture of COVID-19
Nature
-
Comparison of the 2022 and 2017 European LeukemiaNet risk classifications in a real-life cohort of the PETHEMA group
Blood Cancer Journal, Vol. 13, Núm. 1
-
Erratum: Author Correction: Common variants in Alzheimer's disease and risk stratification by polygenic risk scores (Nature communications (2021) 12 1 (3417))
Nature communications
-
Molecular Landscape and Validation of New Genomic Classification in 2668 Adult AML Patients: Real Life Data from the PETHEMA Registry
Cancers, Vol. 15, Núm. 2
-
Rickettsioses imported by travellers and migrants to Spain attended in the +Redivi network, 2009-2020
Journal of travel medicine, Vol. 30, Núm. 3
2022
-
A scoring system for AML patients aged 70 years or older, eligible for intensive chemotherapy: a study based on a large European data set using the DATAML, SAL, and PETHEMA registries
Blood Cancer Journal, Vol. 12, Núm. 7
-
Drug-refractory myasthenia gravis: Clinical characteristics, treatments, and outcome
Annals of Clinical and Translational Neurology, Vol. 9, Núm. 2, pp. 122-131
-
Impact of FLT3–ITD Mutation Status and Its Ratio in a Cohort of 2901 Patients Undergoing Upfront Intensive Chemotherapy: A PETHEMA Registry Study
Cancers, Vol. 14, Núm. 23
-
Long-term survival after intensive chemotherapy or hypomethylating agents in AML patients aged 70 years and older: a large patient data set study from European registries
Leukemia, Vol. 36, Núm. 4, pp. 913-922
-
Metrics of progression and prognosis in untreated adults with thymidine kinase 2 deficiency: An observational study
Neuromuscular Disorders, Vol. 32, Núm. 9, pp. 728-735
-
Muscle MRI characteristic pattern for late-onset TK2 deficiency diagnosis
Journal of Neurology, Vol. 269, Núm. 7, pp. 3550-3562
-
Natural History of MYH7-Related Dilated Cardiomyopathy
Journal of the American College of Cardiology, Vol. 80, Núm. 15, pp. 1447-1461
-
Treatment patterns and outcomes of 2310 patients with secondary acute myeloid leukemia: a PETHEMA registry study
Blood Advances, Vol. 6, Núm. 4, pp. 1278-1295
2021
-
Common variants in Alzheimer's disease and risk stratification by polygenic risk scores
Nature communications, Vol. 12, Núm. 1, pp. 3417
-
Differences in nutritional status and inflammatory biomarkers between female and male patients with bronchiectasis: A large-cohort study
Biomedicines, Vol. 9, Núm. 8
-
Incidence, clinical characteristics and management of inflammatory bowel disease in spain: Large-scale epidemiological study
Journal of Clinical Medicine, Vol. 10, Núm. 13
-
Long runs of homozygosity are associated with Alzheimer’s disease
Translational Psychiatry, Vol. 11, Núm. 1
-
Myelodysplastic syndromes with 20q deletion: incidence, prognostic value and impact on response to azacitidine of ASXL1 chromosomal deletion and genetic mutations
British Journal of Haematology, Vol. 194, Núm. 4, pp. 708-717